Top line decelerating.
+8.6% YoY versus +18.0% prior. 3y CAGR +9.8%.
+8.6%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $277.2B
Fundamentals as of 2025-12-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
2 of 3 legendary models say BUY AZN — but Charlie Munger disagrees.
What would legendary investors pay for AZN?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Bottom line: AZN is rated BUY by all 3 legendary models, 66% below avg fair value $533, but earns a B sector grade (66/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
The Question
+8.6% YoY versus +18.0% prior. 3y CAGR +9.8%.
+8.6%Net margin 17.5% versus 13.0% prior (+4.4pp). Operating 23.4%.
17.5%P/E 28.0x — 64% above the 5y median of 17.1x. Forward 17.0x hints at EPS expansion next year.
28.0xYes — AstraZeneca PLC's 21.0% ROE ranks above the S&P 500 median, and D/E 1.34 stays within healthy bounds.
Financial story
Yes — AstraZeneca PLC's 21.0% ROE shows strong capital efficiency, and its 1.34 debt-to-equity stays within healthy bounds.
How does AZN compare?
AZN trades at 15.5x earnings. Sector context and per-investor signals are in the valuation tab.
AZN and NVS differ on P/E, ROE, and revenue growth. See the full AZN vs NVS compare matrix.
Buffett, Lynch, and Munger evaluate AZN against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
AZN's P/E ratio is 15.5x. 5-year P/E history is in the financials tab.
2 of 3 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
AZN's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
See exactly where AZN ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingAZN sits at #9 in Healthcare with a B grade (66/100).